Bladder Cancer Link Seen Again With A Diabetes Drug
Home / Conditions / Type 2 Diabetes / Bladder Cancer Link Seen Again With A Diabetes Drug Bladder Cancer Link Seen Again With A Diabetes Drug While the risk remains low overall, a new large study showed a greater risk for pioglitazone than other diabetes drugs. Researchers looked at about 146,000 patients in the U.K. who had recently started taking an anti-diabetic drug; those on pioglitazone faced an increased risk of bladder cancer of 121.0 versus 88.9 per 100,000 person-years among those on other diabetes drugs (hazard ratio 1.63, 95% CI 1.22-2.19). Fifty-four patients receiving pioglitazone were diagnosed with cancer after a mean follow-up of 4.7 years. According to lead author Marco Tuccori, PhD, at the Jewish General Hospital in Montreal, Canada, the increased risk was not a class effect. But those on rosiglitazone (Avandia) didnt see an increased risk of bladder cancer (HR 1.10, 95% CI 0.83-1.47). Last year, Actos manufacturer Takeda agreed to pay $2.4 billion to settle lawsuits alleging that it hid from patients bladder cancer risks associated with the drug. Pioglitazone, an antidiabetic drug belonging to the thiazolidinedione class, has been shown to improve glycemic levels in people with type 2 diabetes. However, in 2005, the PROactive randomized controlled trial unexpectedly showed an imbalance in the number of cases of bladder cancer with pioglitazone compared with placebo. In contrast, this imbalance was never observed in randomized controlled trials of rosiglitazone, the other approved drug belonging to the thiazolidinedione class. The findings of the PROactive trial were subsequently corroborated in some, but not all, observational studies. Indeed, in the five-year interim analysis of a large observational study using the Kaiser Permanente Northern Calif Continue reading >>
Diabetes Drug Linked To Increased Bladder Cancer Risk
Diabetes drug linked to increased bladder cancer risk Diabetes drug linked to increased bladder cancer risk "The anti-diabetic drug pioglitazone raises the risk of bladder cancer by 63 per cent," The Daily Telegraph reports. While the actual increased risk in real-world terms is small, the results may help to inform prescription decisions for both doctors and patients. Pioglitazone is a drug that helps people with type 2 diabetes by making their cells more sensitive to insulin. Some previous studies have linked pioglitazone with a raised chance of bladder cancer , although the results ofprevious research have been inconclusive. The new study looked at what happened to 145,806 people who took pioglitazone compared to other oral diabetes drugs (not insulin) over a 14-year period (2000 to 2014). Researchers found that people who had taken pioglitazone, as opposed to other diabetes drugs, were 63% more likely to have been diagnosed with bladder cancer, and that the risk increased the longer they had taken it. It is important to note that the overall risk of bladder cancer was low. There were 121 cases of bladder cancer for every 10,000 people taking pioglitazone for 10 years, compared to 89 cases for people taking other diabetes drugs. For people who respond well to this drug, the benefits in terms of diabetes control are thought to outweigh the risks. Anyone taking pioglitazone should continue the drug as prescribed, but discuss any concerns they have with their doctor, and immediately report any symptoms such as blood in urine, frequent urination, or pain when passing urine. The study was carried out by researchers from the Jewish General Hospital and McGill University, both in Montreal, Canada, and was funded by the Canadian Institutes of Health Research. The study was Continue reading >>
Effect Of Metformin On Mortality Among Diabetic Cancer Patients: A Systematic Review And Meta-analysis | Jnci Cancer Spectrum | Oxford Academic
Most data suggest that cancer patients with diabetes have worse outcomes, which may be reversed with metformin. Metformin might modulate the clinical outcomes of diabetic cancer patients. We performed a systematic review and meta-analysis based on published studies over the past five years to summarize the effects of metformin on diabetic cancer patients. We systematically searched for studies that were published over the past five years. Then, we evaluated these studies for inclusion and extracted the relevant data. The summary risk estimates for the association between metformin treatment and all-cause mortality (ACM) and cancer-specific mortality (CSM) were analyzed using random or fixed-effects models. Stratified analyses by cancer site and country were also conducted. Based on the 42 studies included in our analysis (37 015 diabetic cancer patients), we found a significant benefit associated with metformin treatment on survival corresponding to 27% and 26% reductions in ACM (hazard ratio [HR] = 0.73, 95% confidence interval [CI] = 0.68 to 0.79, P < .001) and CSM (HR = 0.74, 95% CI = 0.64 to 0.86, P < .001), respectively. The ACM rates for colorectal cancer, endometrial cancer, breast cancer, prostate cancer, and ovarian cancer showed significant benefits associated with metformin treatment in our stratified analyses by cancer site. Stratified analyses by cancer site also showed a significant reduction in CSM for breast cancer. This association between metformin treatment and reduced CSM for diabetic breast cancer patients was also observed in our country subgroup analyses. We found an association between metformin exposure and reduced ACM and CSM in diabetic patients with cancer. Our findings suggest that metformin treatment could be an effective treatment option Continue reading >>
- Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System for the Management of Adults With Diabetes | Journal of the Endocrine Society | Oxford Academic
- The interpretation and effect of a low-carbohydrate diet in the management of type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
- Glycaemic control in people with type 2 diabetes mellitus during and after cancer treatment: A systematic review and meta-analysis
Metformin And Gefitinib Cooperate To Inhibit Bladder Cancer Growth Via Both Ampk And Egfr Pathways Joining At Akt And Erk
Article | Open Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk Scientific Reports volume 6, Articlenumber:28611 (2016) EGFR is a potential therapeutic target for treating bladder cancer, but has not been approved for clinical use yet. Metformin is a widely used antidiabetic drug and has demonstrated interesting anticancer effects on various cancer models, alone or in combination with chemotherapeutic drugs. The efficacy of gefitinib, a well-known EGFR tyrosine kinase inhibitor, combined with metformin was assessed on bladder cancer and underlying mechanisms were explored. This drug combination induced a strong anti-proliferative and anti-colony forming effect and apoptosis in bladder cancer cell lines. Gefitinib suppressed EGFR signaling and inhibited phosphorylation of ERK and Akt. Metformin amplified this inhibitory effect and enhanced gefitinib-induced activation of AMPK signaling pathway. In vivo intravesical treatment of metformin and gefitinib on syngeneic orthotopic mice confirmed the significant inhibitory effect on bladder tumor growth. These two drugs may be an excellent combination for the treatment of bladder cancer through intravesical instillation. Bladder cancer is one of the most common cancers of the urinary tract in the world, accounting for about 74,000 new cases and 16,000 deaths in the United State in 2015 1 . Although radical cystectomy with chemotherapy has been applied for treating bladder cancer patients as the standard clinical administration and exerted efficient benefits, recurrence and metastasis take place frequently 2 . To prevent recurrence and progression, intravesical chemotherapy or immunosuppressive agents have been widely used after radical cystectomy 3 , 4 . Continue reading >>
Does Anyone Take Metformin?
2 years 11 months ago - 2 years 11 months ago #48685 by sweetheart238 Dear yoksgrl, i'm too but after 4 months taking Metformin bladder tumor was developed . Agree with you that cancer is the emperor of all maladies Please Log in or Create an account to join the conversation. 2 years 11 months ago #48666 by rocksteady This just may be a coincidence but I had symptom of burning upon urination. I saw my doctor and a urologist.I felt it was caused by something in my diet or meds. I also happened to have started metformin approx 6 months earlier. Before my cystoscope, I stopped metformin because of stomach/ digestive problems. Of course, the burning stopped almost immediately. I told the urologist about it and he just said 'that's good'. The burning came back when I had BCG,so much that I could barely hold it in for 15 minutes but eventually stopped after about the 4th installation. They still haven't told what caused the burning...enlarged prostate, CIS or something else ( like metformin). So I don't know if the metformin played a role, but seeing all these complaints and questions really makes me wonder. btw, it really lowered my A1C Please Log in or Create an account to join the conversation. 2 years 11 months ago #48604 by Harrymack I have been taking metformin for more than 12 years now and January of 2014 I was diagnosed with bladder cancer (5 tumors) after passing blood in urine along with frequent and painful urination for quite some time prior to being diagnosed. I went through 6 treatments of BCG and was clear of cancer for 9 months. Now at 12 months, 2 tumors have recurred that were more aggressive than the previous ones. I recently had the two removed surgically. I am convinced that, after extensive research on the Web, there's a link between metformin and blad Continue reading >>
Pioglitazone Bladder Cancer Link Seen Again
Pioglitazone Bladder Cancer Link Seen Again But absolute risk remains low overall, finds large British study by Parker Brown Parker Brown, Staff Writer, MedPage Today This article is a collaboration between MedPage Today and: Note that this observational study of British patients with diabetes found that the use of pioglitazone, compared with other antidiabetic agents, was associated with an increased risk of bladder cancer. Be aware that the absolute risk of bladder cancer in the population was quite low. Pioglitazone (Actos) was associated with a higher risk of bladder cancer than other diabetes drugs in a large population-based cohort study. Researchers looked at about 146,000 patients in the U.K. who had recently started taking an anti-diabetic drug; those on pioglitazone faced an increased risk of bladder cancer of 121.0 versus 88.9 per 100,000 person-years among those on other diabetes drugs (hazard ratio 1.63, 95% CI 1.22-2.19). Fifty-four patients receiving pioglitazone were diagnosed with cancer after a mean follow-up of 4.7 years. But those on rosiglitazone (Avandia) didn't see an increased risk of bladder cancer (HR 1.10, 95% CI 0.83-1.47), according to lead author Marco Tuccori, PhD , at the Jewish General Hospital in Montreal, Canada, suggesting that the increased risk was not a class effect. Tuccori and colleagues published their findings on Wednesday in The BMJ . In 2015, Actos manufacturer Takeda agreed to pay $2.4 billion to settle lawsuits alleging that it hid bladder cancer risks associated with the drug from patients. The new study is the latest in a long-running seesaw drama, with one study identifying an increased bladder cancer risk with the drug, only to be followed by another showing no link. The latest results support findings from a 2005 tria Continue reading >>
Metformin May Have A Protective Effect In Bladder Cancer Patients
Metformin May Have a Protective Effect in Bladder Cancer Patients Metformin May Have a Protective Effect in Bladder Cancer Patients Diabetics taking the drug had a significant 68% decreased risk of grade progression compared with diabetics not on the drug. Metformin use may decrease the risk of grade progression in patients with non-muscle invasive bladder cancer (NMIBC), according to study findings presented at the Canadian Urological Association 2016 annual meeting in Vancouver. Samer L. Traboulsi, MD, and colleagues at McGill University Health Centre in Montreal conducted a retrospective analysis of 1,356 NMIBC patients with a median age of 69.5 years. The cohort consisted of 1,197 patients (88.3%) without diabetes, 93 patients (6.9%) with diabetes on metformin, and 66 patients (4.9%) with diabetes and not on metformin who served as a reference group. In multivariate analysis, metformin use was not associated with disease recurrence and stage and disease progression, but it was associated with a significant 68% decreased risk of grade progression compared with the reference group. In addition, patients without diabetes had a significant 42% lower risk for disease progression compared with the reference group. Metformin is hypothesized to have antineoplastic activity due to its inhibitor activity on mammalian target of rapamycin, the researchers explained in a poster presentation. Investigations in clinical trials are needed to show whether metformin mitigates the deleterious effect of diabetes on stage progression, Dr. Traboulsi's group concluded. Previously, in a paper published in Urologic Oncology (2015;33:386.e7-386.e13), Canadian researchers reported on a study of 421 patients undergoing radical cystectomy for bladder cancer showing that metformin users had a 6 Continue reading >>
Metformin (glucophage) Side Effects & Complications
The fascinating compound called metformin was discovered nearly a century ago. Scientists realized that it could lower blood sugar in an animal model (rabbits) as early as 1929, but it wasn’t until the late 1950s that a French researcher came up with the name Glucophage (roughly translated as glucose eater). The FDA gave metformin (Glucophage) the green light for the treatment of type 2 diabetes in 1994, 36 years after it had been approved for this use in Britain. Uses of Generic Metformin: Glucophage lost its patent protection in the U.S. in 2002 and now most prescriptions are filled with generic metformin. This drug is recognized as a first line treatment to control blood sugar by improving the cells’ response to insulin and reducing the amount of sugar that the liver makes. Unlike some other oral diabetes drugs, it doesn’t lead to weight gain and may even help people get their weight under control. Starting early in 2000, sales of metformin (Glucophage) were challenged by a new class of diabetes drugs. First Avandia and then Actos challenged metformin for leadership in diabetes treatment. Avandia later lost its luster because it was linked to heart attacks and strokes. Sales of this drug are now miniscule because of tight FDA regulations. Actos is coming under increasing scrutiny as well. The drug has been banned in France and Germany because of a link to bladder cancer. The FDA has also required Actos to carry its strictest black box warning about an increased risk of congestive heart failure brought on by the drug. Newer diabetes drugs like liraglutide (Victoza), saxagliptin (Onglyza) and sitagliptin (Januvia) have become very successful. But metformin remains a mainstay of diabetes treatment. It is prescribed on its own or sometimes combined with the newer d Continue reading >>
New Insight For Metformin Against Bladder Cancer
New insight for metformin against bladder cancer 1Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt 2CAS-TWAS Fellowship at University of Science and Technology of China (USTC), Hefei, 23027 China 1Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt 2CAS-TWAS Fellowship at University of Science and Technology of China (USTC), Hefei, 23027 China Amr Ahmed EL-Arabey, Email: [email protected] , Email: [email protected]_lerma . Received 2016 Oct 30; Accepted 2017 Feb 3. Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( ) applies to the data made available in this article, unless otherwise stated. International Agency for Research on Cancer (IARC) estimated that bladder cancer is the ninth most common cancer in the world, with 430,000 new cases and 165,000 deaths in 2012. Bladder cancer represents the fourth most common cancer in men and ninth most common cancer in women. It is the second most prevalent cancer in men 60years of age or older in United States. Looking further down, continuing advancements in cancer research could potentially offer more choices for clinician and patient with longer survival and better quality of life. Although, bladder cancer represents an ideal tumor model to test and apply cancer prevention strategies; there are limited studies about application of metformin in the man Continue reading >>
Metformin: Can A Diabetes Drug Help Prevent Cancer?
In 1957, the first results from a clinical trial of the diabetes drug metformin in patients were published. Yet, it would take nearly 40 years for the drug to be approved in the United States as a treatment for type 2 diabetes. Now researchers want to know whether this decades-old drug may have additional uses in another disease—cancer. Based on findings from a number of large epidemiologic studies and extensive laboratory research, metformin is being tested in clinical trials not only as a treatment for cancer, but as a way to prevent it in people at increased risk, including cancer survivors who have a higher risk of a second primary cancer. Numerous early-stage clinical trials are currently under way to investigate metformin’s potential to prevent an array of cancers, including colorectal, prostate, endometrial, and breast cancer. Several of these trials are being funded by NCI’s Consortia for Early Phase Prevention Trials. And NCI is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to study participants from the landmark clinical trial, the Diabetes Prevention Program (DPP), to investigate metformin’s impact on cancer incidence. Some of the early-phase prevention trials of metformin are enrolling participants who are at increased risk for cancer and who are obese, have elevated glucose or insulin levels, or have other conditions that put them at risk for diabetes. “With the obesity epidemic, these studies are applicable to a substantial portion of the U.S. population and, increasingly, of the world population,” said Brandy Heckman-Stoddard, PhD, MPH, of NCI’s Division of Cancer Prevention. Expanding the Data Pool Much of the human data on metformin and cancer has come from epidemiologic studies of people w Continue reading >>
Bladder Cancer Risk Factors
Bladder cancer cases linked to exposure to tobacco smoke, UK Bladder cancer cases linked to occupational exposures, UK 42% (44% in males and 37% in females) of bladder cancer cases each year in the UK are linked to major lifestyle and other risk factors[ 1 ] Bladder cancer risk is associated with a number of risk factors[ 2,3 ]. Arsenic and inorganic arsenic compounds[a] Hairdressers and barbers, occupational exposure International Agency for Research on Cancer (IARC) andWorld Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) classifications. a WCRF/AICR classifies evidence on arsenic in drinking water as probable Use our interactive tool to explore risk factors for bladdercancer World Cancer Research Fund / American Institute for Cancer Research. Continuous Update Project Findings & Reports . Accessed October 2016. Tobacco smoking is classified by the International Agency for Research on Cancer (IARC) as a cause of bladder cancer.[ 1 ] An estimated 37% of bladder cancers in the UK are linked to tobacco smoking.[ 2 ] Bladder cancer risk is around 2-4 times higher in current smokers compared with never-smokers, meta-analyseshave shown.[ 3-5 ] Bladder cancer risk increases with amount and duration of smoking, a meta-analysis and pooled analyses of case-control studies have shown.[ 6-8 ] Bladder cancer risk is 73-80% lower in ex-smokers who quit 25 years previously, compared with ongoing smokers, pooled analyses have shown; however, ex-smokers risk remains higher than never-smokers risk.[ 7,8 ] Higher bladder cancer risk in smokers may partly reflect mutual confounding by occupational exposures.[ 9 ] View our health information on smoking and cancer 't Mannetje A, Kogevinas M, Chang-Claude J, et al. Smoking as a confounder in case-control studies of Continue reading >>
- Are You at Risk for Type 2 Diabetes? Learn Common—and Not So Common—Risk Factors
- Symptoms of EARLY diabetes: Five risk factors putting YOU on course for type 2 diabetes
- Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study
Does Pioglitazone Increase The Risk Of Bladder Cancer?
Does pioglitazone increase the risk of bladder cancer? Pioglitazone is a medicine in the glitazone family which may slightly increase the risk of bladder cancer.This is still under investigation, but below is some information about the current concerns. Since 2000, several studies have been running to try to identify a possible link between pioglitazone and bladder cancer. Initial studies were inconclusive. However, there were more spontaneous reports than expected of people on pioglitazone being found to have bladder cancer. A European-wide review in July 2011 found a small increase in the risk of bladder cancer in people taking pioglitazone, especially after long-term use. Assessing people for risk of bladder cancer before starting treatment could help to reduce this small risk and allow people for whom pioglitazone is the best option in terms of their diabetes, to benefit from the drug. Symptoms such as needing to pass urine frequently or pain on passing urine without a clear cause (such as a urine infection) Occupational exposure to certain dyes (used in textiles and industry, probably not standard hair dyes) Certain infections such as schistosomiasis (uncommon in the UK). The advantages of pioglitazone in terms of glucose control may outweigh the risks in some cases. For those taking pioglitaone, tell your doctor if you notice any blood in your urine or any other symptom relating to your urine or bladder. Doctors should review risk of bladder cancer before starting treatment and review the treatment every three to six months. Other factors may also be important as pioglitazone may increase the risk of fractures and of developing pneumonia. More information on risk factors from Cancer Research UK. Recommendations from the European Medical Agency. Continue reading >>
Metformin Fails To Reduce Bladder Cancer Risk, Safer Than Actos: Study
Metformin Fails To Reduce Bladder Cancer Risk, Safer Than Actos: Study Researchers were disappointed to find that the drug metformin did not reduce the risk of bladder cancer among individuals with type 2 diabetes, but they did find that it does not increase the bladder cancer risk, like several studies have suggested side effects of Actos does. In a study published this month in the medical journal Diabetes Care , researchers from the University of Pennsylvanias Abramson Cancer Center found that patients taking metformin or drugs from a class known as sulfonylureas, like Dymelor and Orinase, did not see a reduction in the rate of bladder cancer. Bladder cancer is a potential risk that may be associated with diabetes, and researchers hoped that the diabetes drug metformin may have a prophylactic effect. However, after looking at data involving 87,000 patients with diabetes in The Health Improvement Network, researchers indicate that they found no statistical difference in the bladder cancer rates among those who took the drugs and those who did not. Researchers did recommend scientists take a look at metformin in comparison to other cancer rates as well, as bladder cancer is only one type of cancer some believed metformin may help prevent. Use of metformin is not associated with a decreased incidence of bladder cancer, the researchers concluded. Similar methods should be used to study other cancers that have previously been identified as potentially preventable with metformin. The study comes amid continuing concerns about the link between bladder cancer and Actos , a competing diabetes drug. While all diabetes patients may face a slight increase in the risk of bladder cancer, several studies have suggested that long-term Actus users face a substantially increased risk Continue reading >>
Receive Our Email Newsletter
Metformin Doesnt Decrease Bladder Cancer in Diabetes Patients By Brenda L. MooneyPHILADELPHIA Use of metformin does not decrease the incidence of bladder cancer in patients with diabetes, according to a study looking at new users of drug therapies.The study, published recently in Diabetes Care, found that patients using metformin had similar bladder cancer risk as those using sulfonylureas . Both types of drugs carry a lower risk of bladder cancer than thiazolidinediones (TZD), according to background in the article.1The research was led by Ronac Mamtani, MD, MSCE, assistant professor of medicine at the Hospital of the University of Pennsylvania and attending physician in hematology-oncology at the Philadelphia VAMC.Study authors note that previous investigations evaluating the effect of metformin on cancer risk were affected by time-related biases. To avoid these biases, they write, we examined the incidence of bladder cancer in new users of metformin and sulfonylureas (SUs).Focus on New UsersThe study included 87,600 patients with type 2 diabetes who were part of the Health Improvement Network database in the UK. With diabetes patients at a slightly increased risk of bladder cancer over time, researchers focused only on patients who were new users of either metformin or SUs.In the study group, 196 incident bladder cancer cases were identified in the metformin cohort and 66 cancers in the SU cohort between July 2000 and August 2010. Use of metformin was not associated with decreased bladder cancer risk (HR 0.81 [95% CI 0.601.09]), and the association did not differ by sex (P for interaction = 0.20).In addition, no association was observed with duration of metformin relative to SU use (3 to less than 4 years of use: 0.57 [0.251.34]; 4 to less than 5 years of use: 0.93 Continue reading >>
Can Metformin Cause Bladder Cancer?
Clorazepam Rigevidon Weight Gain Belviq vs Phentermine Brintellix and Alcohol Nexplanon Weight Loss Treato does not review third-party posts for accuracy of any kind, including for medical diagnosis or treatments, or events in general. Treato does not provide medical advice, diagnosis or treatment. Usage of the website does not substitute professional medical advice. The side effects featured here are based on those most frequently appearing in user posts on the Internet. The manufacturer's product labeling should always be consulted for a list of side effects most frequently appearing in patients during clinical studies. Talk to your doctor about which medications may be most appropriate for you. The information reflected here is dependent upon the correct functioning of our algorithm. From time-to-time, our system might experience bugs or glitches that affect the accuracy or correct application of mathematical algorithms. We will do our best to update the site if we are made aware of any malfunctioning or misapplication of these algorithms. We cannot guarantee results and occasional interruptions in updating may occur. Please continue to check the site for updated information. Continue reading >>
- Metformin: Can a Diabetes Drug Help Prevent Cancer?
- High Fructose Corn Syrup (HFCS): A Substance That Cause Autism, Diabetes, Cancer, Liver Failure, Heart Disease, Obesity & Dementia is Now Hidden Under New Name
- Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis
